Experimental Treatments for Parkinson's Disease

Affitope PD01A

Affitope PD01A is an experimental vaccine being developed to treat Parkinson’s. It works by prompting a patient’s immune system to produce antibodies against a man-made peptide that is very similar to alpha-synuclein. It has completed testing in Phase 1 trials.

Learn more

CNM-Au8

CNM-Au8 is an investigational therapy being developed  for Parkinson’s disease and other neurological conditions. It is a concentrated suspension of gold nanocrystals with characteristics that may help protect dopaminergic neurons and improve their survival. A Phase 2 trial is currently recruiting Parkinson’s patients.

Learn more

ND0612

ND0612 is an experimental liquid formulation of levodopa and carbidopa aimed at reducing motor complications, such as involuntary shaking, slowness of movement, or muscle stiffness, in advanced Parkinson’s disease patients. It is designed to be continuously administered beneath the skin. The potential therapy is currently in Phase 2 trials.

Learn more

Nilotinib

Nilotinib is approved under the brand name Tasigna to treat chronic myeloid leukemia, a cancer of the blood. In Parkinson’s disease, nilotinib also may work to eliminate toxic proteins that build in the brain by activating a mechanism in brain cells that serves as a sort of garbage disposal unit. It is being tested in Phase 2 trials.

Learn more

NPT520-34

NPT520-34 is an experimental small-molecule therapy that has been shown to reduce neuroinflammation in preclinical studies of Parkinson’s disease. It is administered orally and is small enough to be able to cross the blood-brain barrier, a highly selective, semipermeable membrane that isolates the brain from the blood circulating in the body. The potential therapy is currently in Phase 1 testing.

Learn more

NTCELL

NTCELL is an investigative disease-modifying therapy for Parkinson’s consists of a microcapsule implanted into a damaged site within the brain. Preclinical studies of NTCELL have shown that it has the capacity to regenerate damaged tissue and restore nerve cell function in animal models of Parkinson’s. It was last studied in a Phase 2 trial, but its current status is unknown.

Learn more

PF-05251749

PF-05251749 is an experimental oral therapy for “sundowning” in Alzheimer’s disease and irregular sleep-wake rhythm disorder in Parkinson’s disease. PF-05251749 is a small molecule that inhibits CK1E, a key enzyme involved in regulating circadian rhythms, preventing “nighttime” proteins from being produced during the day. It has been studied in Phase 1 trials in healthy volunteers.

Learn more

PRX002

PRX002 (also known as RG7935) is an investigational monoclonal antibody being developed to slow the progression of Parkinson’s disease. It is a type of disease-modifying immunotherapy aimed at harness the body’s immune system to remove the toxic alpha-synuclein — possibly preventing or slowing alpha-synuclein-related neurodegeneration. It is currently in Phase 2 trials.

Learn more

VY-AADC

VY-AADC is a gene therapy being developed for Parkinson’s disease. It is aimed at increasing the patient’s ability to produce dopamine, a signaling molecule that helps regulate movement and emotional responses, which improves motor function and reduces the need for other Parkinson’s medications. The potential therapy is being tested in Phase 2 trials.

Learn more
Books icon

Your Parkinson's Community

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community. These forums are designed for patients, caregivers, and medical professionals to discuss issues, ask questions, and share experiences.

View Forums
Speech bubble icon